Bleeding diathesis: Difference between revisions
Line 59: | Line 59: | ||
! rowspan="16" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelet disorders | ! rowspan="16" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelet disorders | ||
! rowspan="7" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Thrombocytopenia]] | ! rowspan="7" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Thrombocytopenia]] | ||
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Infection]]-Induced [[thrombocytopenia]] | ! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Infection]]-Induced [[thrombocytopenia]]<ref name="HerbingerSchunk2012">{{cite journal|last1=Herbinger|first1=K.-H.|last2=Schunk|first2=M.|last3=Nothdurft|first3=H. D.|last4=von Sonnenburg|first4=F.|last5=Löscher|first5=T.|last6=Bretzel|first6=G.|title=Comparative study on infection-induced thrombocytopenia among returned travellers|journal=Infection|volume=40|issue=4|year=2012|pages=373–379|issn=0300-8126|doi=10.1007/s15010-012-0242-9}}</ref> | ||
| align="left" style="background:#F5F5F5;" | | | align="left" style="background:#F5F5F5;" | | ||
* History of prior infection | * History of prior infection | ||
Line 75: | Line 76: | ||
| align="center" style="background:#F5F5F5;" | − | | align="center" style="background:#F5F5F5;" | − | ||
|- | |- | ||
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Medication]]-Induced [[Thrombocytopenia|Thrombocytopenia]] | ! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Medication]]-Induced [[Thrombocytopenia|Thrombocytopenia]]<ref name="EltingCantor2003">{{cite journal|last1=Elting|first1=Linda S.|last2=Cantor|first2=Scott B.|last3=Martin|first3=Charles G.|last4=Hamblin|first4=Lois|last5=Kurtin|first5=Danna|last6=Rivera|first6=Edgardo|last7=Vadhan-Raj|first7=Saroj|last8=Benjamin|first8=Robert S.|title=Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors|journal=Cancer|volume=97|issue=6|year=2003|pages=1541–1550|issn=0008-543X|doi=10.1002/cncr.11195}}</ref> | ||
| align="left" style="background:#F5F5F5;" | | | align="left" style="background:#F5F5F5;" | | ||
*History of [[Medication|medications]] such as: | *History of [[Medication|medications]] such as: | ||
Line 99: | Line 100: | ||
| align="center" style="background:#F5F5F5;" | Most important part of treatment is discontinuing of the medication. | | align="center" style="background:#F5F5F5;" | Most important part of treatment is discontinuing of the medication. | ||
|- | |- | ||
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Heparin-Induced Thrombocytopenia|Heparin-Induced thrombocytopenia]] | ! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Heparin-Induced Thrombocytopenia|Heparin-Induced thrombocytopenia]]<ref name="Miller2003">{{cite journal|last1=Miller|first1=Penny L.|title=Heparin-induced Thrombocytopenia Recognition and Treatment|journal=AORN Journal|volume=78|issue=1|year=2003|pages=79–89|issn=00012092|doi=10.1016/S0001-2092(06)61348-3}}</ref> | ||
| align="left" style="background:#F5F5F5;" | | | align="left" style="background:#F5F5F5;" | | ||
* [[Thrombosis]] | * [[Thrombosis]] | ||
Line 116: | Line 117: | ||
| align="center" style="background:#F5F5F5;" | For more information click here: [[Heparin-induced thrombocytopenia]]. | | align="center" style="background:#F5F5F5;" | For more information click here: [[Heparin-induced thrombocytopenia]]. | ||
|- | |- | ||
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Idiopathic thrombocytopenic purpura|Immune Thrombocytopenic Purpura]] | ! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Idiopathic thrombocytopenic purpura|Immune Thrombocytopenic Purpura]]<ref name="CurtisKaliszewski2006">{{cite journal|last1=Curtis|first1=Brian R.|last2=Kaliszewski|first2=James|last3=Marques|first3=Marisa B.|last4=Saif|first4=M. Wasif|last5=Nabelle|first5=Lisle|last6=Blank|first6=Jules|last7=McFarland|first7=Janice G.|last8=Aster|first8=Richard H.|title=Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin|journal=American Journal of Hematology|volume=81|issue=3|year=2006|pages=199–201|issn=0361-8609|doi=10.1002/ajh.20516}}</ref> | ||
| align="left" style="background:#F5F5F5;" | | | align="left" style="background:#F5F5F5;" | | ||
* History of prior [[infection]] or no history | * History of prior [[infection]] or no history | ||
Line 132: | Line 133: | ||
| align="center" style="background:#F5F5F5;" | − | | align="center" style="background:#F5F5F5;" | − | ||
|- | |- | ||
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Inherited [[Thrombocytopenia]] | ! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Inherited [[Thrombocytopenia]]<ref name="Drachman2004">{{cite journal|last1=Drachman|first1=J. G.|title=Inherited thrombocytopenia: when a low platelet count does not mean ITP|journal=Blood|volume=103|issue=2|year=2004|pages=390–398|issn=0006-4971|doi=10.1182/blood-2003-05-1742}}</ref> | ||
| align="left" style="background:#F5F5F5;" | | | align="left" style="background:#F5F5F5;" | | ||
* Positive family history | * Positive family history | ||
Line 148: | Line 149: | ||
| align="center" style="background:#F5F5F5;" | − | | align="center" style="background:#F5F5F5;" | − | ||
|- | |- | ||
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Thrombotic thrombocytopenic purpura|Thrombotic Thrombocytopenic Purpura]] | ! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Thrombotic thrombocytopenic purpura|Thrombotic Thrombocytopenic Purpura]]<ref name="George2006">{{cite journal|last1=George|first1=James N.|title=Thrombotic Thrombocytopenic Purpura|journal=New England Journal of Medicine|volume=354|issue=18|year=2006|pages=1927–1935|issn=0028-4793|doi=10.1056/NEJMcp053024}}</ref> | ||
| align="left" style="background:#F5F5F5;" | History of: | | align="left" style="background:#F5F5F5;" | History of: | ||
*[[Cancer]] | *[[Cancer]] | ||
Line 170: | Line 171: | ||
| align="center" style="background:#F5F5F5;" | − | | align="center" style="background:#F5F5F5;" | − | ||
|- | |- | ||
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Hemolytic-uremic syndrome|Hemolytic Uremic Syndrome]] | ! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Hemolytic-uremic syndrome|Hemolytic Uremic Syndrome]]<ref name="Noris2005">{{cite journal|last1=Noris|first1=M.|title=Hemolytic Uremic Syndrome|journal=Journal of the American Society of Nephrology|volume=16|issue=4|year=2005|pages=1035–1050|issn=1046-6673|doi=10.1681/ASN.2004100861}}</ref> | ||
| align="left" style="background:#F5F5F5;" |History of: | | align="left" style="background:#F5F5F5;" |History of: | ||
* [[Infections]] | * [[Infections]] |
Revision as of 18:06, 19 October 2018
Bleeding diathesis main page |
|
---|
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [2], Nazia Fuad M.D., Sogand Goudarzi, MD [3]
Synonyms and keywords: Hypocoagulopathy; Bleeding disorders.
Overview
Bleeding diathesis is susceptibility to bleed due to coagulopathy disorders or platelets disorders. These diseases can occur due to a disorder of homeostasis, localized process (tissue injury), or medications. Bleeding diathesis can be resulted from vessel wall injury, platelet disorders, and coagulation factor disorders. Clinical manifestation of bleeding disorders can have a wide range of symptoms from asymptomatic to symptomatic massive and life threatening bleeding. Platelet disorders mostly have skin manifestations such as petechiae, and ecchymoses. In order to find the cause of hypo-coagulopathy; there are established laboratory tests, such as peripheral blood smear, platelet count and platelet function analysis, coagulation factor deficiencies and inhibitors, fibrinolysis tests (eg. D-dimer level), bleeding time (BT), prothrombin time (PT), activated partial thromboplastin time (aPTT), thrombin time (TT), and reptilase time. In the case of any abnormal bleeding, first line of screening tests are CBC, PT, PTT, BT, and TT.[1]
Classification
Disorders of hemostasis can be classified into two main categories: platelet disorders, and disorders of coagulation. Each category can be further classified as bellow:
Abnormal hemostasis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
•Patient history-sign & symptom: Deep soft tissue bleeding Mucocutaneus bleeding •Screen test CBBC-plt-PT&PTT-BT-TT | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hx of deep soft tissue bleeding | Hx of mucocotaneus bleeding | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Coagulopathy | Plt disorder | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Family history | Normal plt count | Low plt count | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(+) •Inherited coagulpathy | (-) •Aquired coagulopathy | Functional Plt disorder | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
↑Plt •Hemophillia •VWD •FactorVIII or IX deficiency | ↑PT • Factor VII deficiensy | ↑PT&↑PTT •Fibrinogen deficiency •FactorII deficiency •FactorV deficiency •FactorX deficiency | ↑PTT •Factor inhibitor •Anti phospholipid A6syndrome | ↑PT •Factor inhibitor •VitK deficiency •Liver disease | ↑PT&↑PTT •Factor inhibit •DIC •Liver failure •late stage of VitK deficincy | ↑Afibrinogenia •Heparin inhibitor •Direct thrombin inhibitor | Abnormal solobity •FactorXIII deficincy •Cross-linkin inhibitor | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Not corrected with mixing with NL plasma | HX(+) | HX(-) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
•Factor inhibitors •Lupus anti coagulant •DIC •Heparin or direct thrombin inhibitors | Congenital | Acquired | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Differentiating Bleeding Disorders from Other Diseases
Different causes of bleeding disorders can be differentiated based on their clinical manifestation and laboratory findings.
These features have discussed in the below table:
Category | Subcategory | Disease | History | Clinical manifestation | Laboratory testing | Comments | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mucosal bleeding | Petechia | Ecchymoses | Menorrhagia | Hematoma | Hemarthrosis | Plt | BT | PT | PTT | TT | ||||||
Platelet disorders | Thrombocytopenia | Infection-Induced thrombocytopenia[2] |
|
+ | + | + | + | + | + | ↓ | ↑ | Nl | Nl | Nl | − | |
Medication-Induced Thrombocytopenia[3] |
|
+ | + | + | + | + | + | ↓ | ↑ | Nl | Nl | Nl | Most important part of treatment is discontinuing of the medication. | |||
Heparin-Induced thrombocytopenia[4] |
|
+ | + | + | + | + | + | ↓ | ↑ | Nl | Nl | ↑ | For more information click here: Heparin-induced thrombocytopenia. | |||
Immune Thrombocytopenic Purpura[5] |
|
+ | + | + | + | + | + | ↓ | ↑ | Nl | Nl | Nl | − | |||
Inherited Thrombocytopenia[6] |
|
+ | + | + | + | + | + | ↓ | ↑ | Nl | Nl | Nl | − | |||
Thrombotic Thrombocytopenic Purpura[7] | History of:
|
+ | + | + | + | + | + | ↓ | ↑ | Nl | Nl | Nl | − | |||
Hemolytic Uremic Syndrome[8] | History of: | + | + | + | + | + | + | ↓ | ↑ | Nl | Nl | Nl | − | |||
Subcategory | Disease | History | Mucosal bleeding | Petechia | Ecchymoses | Menorrhagia | Hematoma | Hemarthrosis | Plt | BT | PT | PTT | TT | Comments | ||
Thromobcytosis | Iron deficiency anemia
Inflammatory diseases |
− | − | − | − | ± | ± | ↑ | Nl or ↑ | Nl | Nl | Nl | − | |||
Qualitative Disorders of Platelet Function | Inherited Disorders of Platelet Function | Glanzmann’s thrombasthenia |
|
+ | + | + | + | − | Rare | Nl or ↓ | ↑ | Nl | Nl | Nl |
| |
Bernard-Soulier syndrome |
|
+ | + | + | + | − | − | Nl or ↓ | ↑ | Nl | Nl | Nl |
| |||
Wiskott-Aldrich syndrome |
|
+ | + | + | + | − | − | Nl or ↓ | ↑ | Nl | Nl | Nl | ||||
Platelet storage pool disorder: |
|
+ | + | + | + | − | − | Nl or ↓ | ↑ | Nl | Nl | Nl |
| |||
Acquired Disorders of Platelet Function |
|
+ | + | + | + | ± | ± | Nl or ↓ | ↑ | Nl | Nl | Nl | − | |||
Von Willebrand Disease |
|
+ | + | + | + | ± | ± | ↑ | Nl | ↑ | ↑ | Nl | See the table below for the details about different types. | |||
Subcategory | Disease | History | Mucosal bleeding | Petechia | Ecchymoses | Menorrhagia | Hematoma | Hemarthrosis | Plt | BT | PT | PTT | TT | Comments | ||
Vessel wall disorders | Metabolic and Inflammatory Disorders |
|
|
− | + | + | ± | − | − | Nl | Nl or ↑ | Nl | Nl | Nl | − | |
Inherited Disorders of the Vessel Wall |
|
− | + | + | ± | − | − | Nl | Nl or ↑ | Nl | Nl | Nl | − | |||
Coagulation factor disorders | Fibrinogen deficiency |
Different types of the fibrinogen disorders: |
|
− | − | + | + | ± | + | Nl | ↑ | ↑ | ↑ | ↑ |
| |
Subcategory | Disease | History | Mucosal bleeding | Petechia | Ecchymoses | Menorrhagia | Hematoma | Hemarthrosis | Plt | BT | PT | PTT | TT | Comments | ||
Prothrombin deficiency |
|
− | + | + | + | + | + | Nl | Nl | ↑ | ↑ | ↑ | − | |||
Factor V deficiency |
|
− | − | + | + | + | + | Nl | ↑ | ↑ | ↑ | Nl |
| |||
Factor VII deficiency |
|
+ | + | + | Nl | ↑ | Nl | Nl |
| |||||||
Factor X deficiency |
|
+ | + | + | + | + | Nl | Nl | ↑ | ↑ | Nl | − | ||||
Factor XII deficiency |
|
− | − | − | − | − | Nl | Nl | Nl | ↑ | Nl | |||||
Subcategory | Disease | History | Mucosal bleeding | Petechia | Ecchymoses | Menorrhagia | Hematoma | Hemarthrosis | Plt | BT | PT | PTT | TT | Comments | ||
High molecular weight kininogen (HMWK) deficiency |
|
− | − | − | − | − | Nl | Nl | Nl | ↑ | Nl | |||||
Prekallikrein deficiency |
|
− | − | − | − | − | Nl | Nl | Nl | ↑ | Nl | |||||
Factor XIII deficiency |
|
|
± | ± | ± | ± | ± | ± | Nl | Nl | Nl or ↑ | Nl | Nl |
| ||
Hemophilia | Type A deficiency |
|
− | − | − | + | + | + | Nl | Nl | Nl | ↑ | Nl | − | ||
Type B deficiency |
|
− | − | − | + | + | + | Nl | Nl | Nl | ↑ | Nl | − | |||
Type C deficiency |
|
− | − | − | + | Rare | Rare | Nl | Nl | Nl | ↑ | Nl | − | |||
Subcategory | Disease | History | Mucosal bleeding | Petechia | Ecchymoses | Menorrhagia | Hematoma | Hemarthrosis | Plt | BT | PT | PTT | TT | Comments | ||
Rare diseases | Disseminated Intravascular Coagulation |
|
+ | + | + | + | + | + | ↓ | ↑ | ↑ | ↑ | Nl | − | ||
Vitamin K Deficiency |
|
+ | − | + | + | + | + | Nl | ↑ | ↑ | Nl or mildly prolonged | Nl | − |
Different types of Von-Willebrand diseases
Type of VWD | Type of factor deficiency | Prevalence | Inheritance pattern | Clinical manifestations | VWF activity | RIPA | Factor VIII | |
---|---|---|---|---|---|---|---|---|
Type 1 | Quantitative/ partial | 60-70% | AD |
|
↓ | ↓ | ↓ | |
Type 2 | 2A | Qualitative | 10% | AD/AR |
|
↓ | ↓ | N or ↓ |
2B | Qualitative | 5% | AD |
|
↓ | ↑ | N or ↓ | |
2M | Qualitative | <1% | AD/AR |
|
↓ | ↓ | N or ↓ | |
2N | Qualitative | <1% | AR |
|
N | N | ↓ | |
Type 3 | Complete deficiency | 1-2% | AR |
|
Absent | ↓ | Low, 1-10% |
For more information on Von Willebrand disease, click here.
References
- ↑ Posan E, McBane RD, Grill DE, Motsko CL, Nichols WL (September 2003). "Comparison of PFA-100 testing and bleeding time for detecting platelet hypofunction and von Willebrand disease in clinical practice". Thromb. Haemost. 90 (3): 483–90. doi:10.1160/TH03-02-0111. PMID 12958618.
- ↑ Herbinger, K.-H.; Schunk, M.; Nothdurft, H. D.; von Sonnenburg, F.; Löscher, T.; Bretzel, G. (2012). "Comparative study on infection-induced thrombocytopenia among returned travellers". Infection. 40 (4): 373–379. doi:10.1007/s15010-012-0242-9. ISSN 0300-8126.
- ↑ Elting, Linda S.; Cantor, Scott B.; Martin, Charles G.; Hamblin, Lois; Kurtin, Danna; Rivera, Edgardo; Vadhan-Raj, Saroj; Benjamin, Robert S. (2003). "Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors". Cancer. 97 (6): 1541–1550. doi:10.1002/cncr.11195. ISSN 0008-543X.
- ↑ Miller, Penny L. (2003). "Heparin-induced Thrombocytopenia Recognition and Treatment". AORN Journal. 78 (1): 79–89. doi:10.1016/S0001-2092(06)61348-3. ISSN 0001-2092.
- ↑ Curtis, Brian R.; Kaliszewski, James; Marques, Marisa B.; Saif, M. Wasif; Nabelle, Lisle; Blank, Jules; McFarland, Janice G.; Aster, Richard H. (2006). "Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin". American Journal of Hematology. 81 (3): 199–201. doi:10.1002/ajh.20516. ISSN 0361-8609.
- ↑ Drachman, J. G. (2004). "Inherited thrombocytopenia: when a low platelet count does not mean ITP". Blood. 103 (2): 390–398. doi:10.1182/blood-2003-05-1742. ISSN 0006-4971.
- ↑ George, James N. (2006). "Thrombotic Thrombocytopenic Purpura". New England Journal of Medicine. 354 (18): 1927–1935. doi:10.1056/NEJMcp053024. ISSN 0028-4793.
- ↑ Noris, M. (2005). "Hemolytic Uremic Syndrome". Journal of the American Society of Nephrology. 16 (4): 1035–1050. doi:10.1681/ASN.2004100861. ISSN 1046-6673.
- ↑